Business Context and Reporting Period
Company: BioLineRx Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2011
Business Overview: BioLineRx is a clinical-stage biopharmaceutical development company incorporated in Israel. The company focuses on identifying, in-licensing, and developing therapeutic candidates for unmet medical needs. As of the reporting date, the company had no commercial products on the market and generated no product revenue. Its strategy relies heavily on out-licensing arrangements with third parties (e.g., Ikaria, Cypress Bioscience) to fund development and commercialization.
Key Financial Metrics (Year Ended Dec 31, 2011)
| Metric | Value (NIS '000s) | Value (USD '000s) |
|---|---|---|
| Revenues | 0 | 0 |
| Cost of Revenues | 0 | 0 |
| Research & Development Expenses | (42,623) | (11,155) |
| Sales & Marketing Expenses | (3,308) | (866) |
| General & Administrative Expenses | (12,722) | (3,329) |
| Operating Loss | (58,653) | (15,350) |
| Net Loss | (50,186) | (13,134) |
| Net Loss Per Share | (0.41) | (0.11) |
| Cash & Cash Equivalents | 33,061 | 8,652 |
| Short-term Bank Deposits | 65,782 | 17,216 |
| Total Assets | 111,660 | 29,222 |
| Total Liabilities | 25,902 | 6,779 |
| Shareholders' Equity | 85,758 | 22,443 |
Note: USD amounts are translated at the period-end exchange rate of NIS 3.821 per USD. The company reported zero revenue for 2011, a significant drop from 2010 when it recognized $30 million from a Cypress Bioscience deal.
Material Changes vs. Prior Period
- Revenue Collapse: Revenues dropped from NIS 113.2 million ($30.0 million) in 2010 to zero in 2011. The 2010 revenue was driven by a $30 million upfront payment from Cypress Bioscience for the BL-1020 license, which was terminated in May 2011 when BioLineRx reacquired the rights.
- Operating Loss: The company swung from an operating income of NIS 13.1 million in 2010 to an operating loss of NIS 58.7 million in 2011, primarily due to the loss of the Cypress revenue and continued R&D spending.
- R&D Expenses: R&D expenses decreased by 22% (NIS 12.4 million) compared to 2010. However, excluding a one-time NIS 17.4 million repayment to the Israeli Office of the Chief Scientist (OCS) recorded in 2010, R&D expenses actually increased by 14% in 2011 due to the commencement of the CLARITY clinical trial for BL-1020.
- Liquidity: Cash and short-term deposits decreased from NIS 139.8 million in 2010 to NIS 98.8 million in 2011, reflecting the burn rate of clinical trials and the absence of large licensing inflows.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management believes that following a private placement completed in February 2012 (raising approx. $15 million), existing cash resources will be sufficient to fund operations into the second quarter of 2014. The company expects to continue incurring significant losses as it advances its pipeline. Future funding will likely require additional equity or debt financings, or milestone payments from partners.
Key Pipeline Updates:
- BL-1020 (Schizophrenia): Reacquired rights from Cypress Bioscience in May 2011. Commenced the Phase 2/3 CLARITY trial in June 2011 (Romania and India).
- BL-1040 (Cardiac Remodeling): Out-licensed to Ikaria. Ikaria commenced the PRESERVATION 1 CE Mark registration trial in December 2011.
- BL-5010 (Skin Lesions): Completed Phase 1/2 trial with positive results; evaluating commercialization strategy.
- BL-1021 (Neuropathic Pain): Completed Phase 1a safety trial in December 2011.
- BL-7040 (IBD): Received Israeli Ministry of Health approval in March 2012 to commence Phase 2 study.
Material Risks:
- Regulatory Approval: No products are approved; failure in clinical trials or regulatory rejection would halt revenue generation.
- Liquidity: History of losses and accumulated deficit of NIS 368.1 million. Dependence on future financing and milestone payments.
- Out-Licensing Dependence: Reliance on partners (Ikaria) for development and commercialization of key assets.
- Israeli Government Restrictions: Significant R&D funding from the OCS comes with restrictions on transferring technology or manufacturing outside Israel without approval and potential high royalty repayments (up to 300% of grants).
- Geopolitical Risk: Operations are based in Israel; regional instability could disrupt operations or affect employee availability (military reserve duty).
Investor Verification Checklist
- Cash Runway: Verify the actual cash balance post-February 2012 private placement and confirm the burn rate against the "Q2 2014" liquidity projection.
- BL-1020 Trial Status: Confirm enrollment rates and interim data from the CLARITY Phase 2/3 trial, as this is the primary asset for potential future revenue.
- OCS Obligations: Review the specific terms of the OCS grants and loans to understand potential future repayment liabilities if manufacturing or licensing occurs outside Israel.
- Ikaria Milestones: Monitor the progress of the PRESERVATION 1 trial for BL-1040 to assess the likelihood of receiving future milestone payments (up to $265.5 million potential).
- Stock Dilution: Assess the impact of the February 2012 private placement (5.25 million ADSs) and associated warrants on existing shareholder equity.